1Ettinger B;Black DM;Mitlak BH.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial.multiple outcomes of raloxifene evaluation (MORE) investigation[J],1999(7).
2Stamper MJ;Hu FB;Manson.Primary prevention of coronary heart disease in women through diet and lifestyle[J],2000.
3Kloosterboer HJ.Tissue-selective effects of tibolone on the breast[J],2004(1).
4Shunmaker SA;Legault C;Rapp SR.Estrogen plus progestin and the risk of dementia and mild cognitive impatient in postmenopausal women.The Women's Health Memory Study:a randomized controlled trial,2003.
5Hulley S;Grady D;Bush T.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.Heart and Estrogen/progestin Replacement Study (HERS) Research Group[J],1998(7).
6Stamper MJ;Colditz GA;Willett WC.Postmenopausal estrogen therapy and cardiovascular disease.Ten-year follow-up from the Nurse's Health Study,1991.
7Zandi PP;Carlson MC;Plassman BL.Hormone replacement therapy and incidence of Aalzheimer's disease in older women:the UCHE County Study,2002.
8Wells G;Tugwell P;Shea B.Ⅴ Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women[J],2002(4).
9Cardozo L;Bachmann G;McClish D.Meta-analysis ofestrogen therapy in the management of urogenital atrophy in postmenopausal women:second report of the Hormones and Urogenital Therapy Committee[J],1998(4 Pt 2).
10Million Women Study Collaborators.Breast cancer and hormone replacement therapy in the million women study[J],2003(9382).
